The World is Falling Behind in the Fight Against Hepatitis C: Will We Meet the 2030 Deadline?
The clock is ticking on the World Health Organization’s (WHO) ambitious goal to eliminate hepatitis C (HCV) by 2030, but new research reveals a stark reality: we’re not on track. Despite significant strides, gaps in progress persist, leaving millions at risk. But here’s where it gets controversial: while some countries are soaring ahead, others are struggling to even meet basic benchmarks. Could this disparity widen global health inequalities?
Presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2025, Zoe Ching, a Data Dashboard Intern at the Coalition for Global Hepatitis Elimination, unveiled findings that shed light on the global effort. The study analyzed progress toward WHO’s elimination targets: reducing HCV incidence to <5 new infections per 100,000 people and mortality to <2 per 100,000. The results? Only 15% of countries are on track for mortality reduction, and a mere 14% for incidence. And this is the part most people miss: even among the 10 countries meeting both targets, six are in the Americas, leaving other regions far behind.
Globally, an estimated 50 million people live with HCV, with 6,000 new infections daily. In response, WHO declared HCV a global health threat in 2015 and introduced the Path to Elimination (PTE) framework, categorizing progress into bronze, silver, and gold tiers based on prevention, diagnosis, and treatment coverage. For instance, gold status requires diagnosing ≥80% of infected individuals, treating ≥70%, and distributing >150 needles/syringes annually per person who injects drugs.
The study, drawing data from 167 countries, highlights uneven progress. In needle/syringe coverage, 39% of countries reached bronze, but only 7% achieved gold. Diagnosis and treatment coverage fared worse, with just 6% and 6% of countries, respectively, meeting gold standards. Here’s the kicker: no countries in the Southeast Asia Region even reached bronze-tier thresholds.
Country-specific insights reveal both hope and challenges. The United States, for example, achieved bronze-tier diagnosis coverage (68%) but only 43% treatment coverage. Egypt and Norway, however, earned gold for treatment, while Australia, Georgia, and Spain secured silver.
“Challenges remain for most countries,” noted Choi and colleagues, emphasizing the need for resource allocation, expanded treatment access, and scaled-up screening. But here’s the question: Are we doing enough to bridge these gaps? And if not, what will it take to ensure no one is left behind?
As we approach 2030, the fight against HCV demands urgent action, collaboration, and accountability. Will we rise to the challenge, or will this deadline slip through our fingers? Let’s keep the conversation going—share your thoughts in the comments below.
For more updates from The Liver Meeting 2025, click here: https://www.eatg.org/hiv-news/highlights-from-the-liver-meeting-2025/.
